Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xeljanz tofacitinib Cancelled
Xeljanz tofacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Xeljanz Tofacitinib Arthritis, rheumatoid List with criteria/condition Complete
Xcopri cenobamate Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban (granules for oral suspension) Venous Thromboembolic Events CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xarelto Rivaroxaban Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. Reimburse with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Thromboembolism (venous), prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolism, prevention N/A Complete
Xarelto Rivaroxaban Atrial fibrillation, stroke prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism List with clinical criteria and/or conditions Complete